What is the treatment for cryptogenic organizing pneumonia (COP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The primary treatment for organizing pneumonia is corticosteroid therapy, typically starting with prednisone at 0.5-1 mg/kg/day (usually 40-60 mg daily) for 1-3 months, followed by a slow taper over 3-6 months to prevent relapse. This recommendation is based on the most recent and highest quality study available, which suggests that corticosteroids are effective in treating organizing pneumonia, with most patients responding dramatically within days to weeks with clinical and radiographic improvement 1.

Treatment Approach

The treatment approach for organizing pneumonia involves:

  • Starting with prednisone at 0.5-1 mg/kg/day (usually 40-60 mg daily) for 1-3 months
  • Slowly tapering the dose over 3-6 months to prevent relapse
  • Considering immunosuppressive agents like cyclophosphamide, azathioprine, or mycophenolate mofetil for steroid-resistant cases
  • Using macrolide antibiotics such as azithromycin (250-500 mg three times weekly) as steroid-sparing agents in mild cases or for maintenance therapy

Rationale

The therapeutic effect of steroids relates to their potent anti-inflammatory properties, suppressing the excessive immune response that leads to fibroblast proliferation and matrix deposition in the alveolar spaces 1. Regular follow-up with pulmonary function tests and imaging is essential to assess treatment response and guide the tapering schedule.

Key Considerations

  • Treatment duration typically ranges from 6-12 months total, with close monitoring for response and side effects
  • The majority of patients recover completely with oral corticosteroids, but relapse is common
  • Some cases may be characterized by residual or progressive interstitial fibrosis, with or without recurrent episodes of organizing pneumonia 1

From the Research

Organizing Pneumonia Treatment Overview

  • Organizing pneumonia is a clinical and pathological syndrome that describes a lung injury caused by an inflammatory reaction in the alveolar connective tissue 2.
  • It can be secondary to infection, drug toxicity, connective tissue disorders, inhalation injuries, organ transplant, or radiotherapy, and also can be idiopathic 2.

Corticosteroids as a Treatment Option

  • Corticosteroids are standard therapy for organizing pneumonia, but the question of whether an approach with high dose corticosteroids would be beneficial for patients with organizing pneumonia secondary to COVID-19 remains to be answered 3.
  • A systematic review of the literature on systemic corticosteroid treatment for organizing pneumonia found that most patients were started on treatment with systemic corticosteroids, but there was a great heterogeneity regarding drug, doses, and duration 4.
  • The findings of this systematic review show the low quality data supporting the use of corticosteroids for the treatment of organizing pneumonia, highlighting a need to undertake appropriately designed studies to investigate which is the most appropriate treatment regimen that trades off benefits and risks of prolonged corticosteroid administration 4.

Alternative Treatment Options

  • Clarithromycin has been used as an alternative treatment for organizing pneumonia, particularly for patients in good clinical status and in whom the probability of adverse events in the course of corticotherapy is high 5.
  • A review of the organizing pneumonias discussed the use of second-line treatment options for corticosteroid-refractory forms of OP, including cyclophosphamide, azathioprine, and cyclosporin 6.

Treatment Considerations

  • Approximately 70% of patients treated with corticosteroids relapse even during initial treatment, and multiple and late relapses occur in about one-third of the patients 6.
  • The initiation of the OP tissue response in the bronchiolar and sub-bronchiolar location may be due to the presence of bronchiolar-associated lymphoid tissue found at the bifurcations of the bronchioles, and repair requires intrabronchiolar formation of granulation tissue and a favorable ratio of matrix metalloproteinase to tissue inhibitors of metalloproteinase (MMP : TIMP) within the stroma 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

A review of organizing pneumonia.

JAAPA : official journal of the American Academy of Physician Assistants, 2023

Research

Organizing pneumonia: A late phase complication of COVID-19 responding dramatically to corticosteroids.

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2021

Research

[Organizing pneumonia--clarithromycin treatment].

Pneumonologia i alergologia polska, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.